Keudell Morrison Wealth Management Purchases Shares of 5,149 Eli Lilly and Company $LLY

Keudell Morrison Wealth Management acquired a new position in shares of Eli Lilly and Company (NYSE:LLY) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 5,149 shares of the company’s stock, valued at approximately $5,534,000. Eli Lilly and Company comprises approximately 1.2% of Keudell Morrison Wealth Management’s portfolio, making the stock its 19th biggest holding.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Capital Research Global Investors raised its holdings in Eli Lilly and Company by 20.9% during the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after purchasing an additional 4,332,008 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Eli Lilly and Company by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock worth $88,087,193,000 after buying an additional 1,006,885 shares during the period. Amundi increased its position in shares of Eli Lilly and Company by 27.1% during the third quarter. Amundi now owns 4,525,902 shares of the company’s stock worth $3,823,977,000 after buying an additional 964,675 shares during the period. Jennison Associates LLC raised its stake in Eli Lilly and Company by 22.3% during the fourth quarter. Jennison Associates LLC now owns 5,133,676 shares of the company’s stock worth $5,517,059,000 after buying an additional 937,204 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its holdings in Eli Lilly and Company by 47.6% in the third quarter. Victory Capital Management Inc. now owns 2,309,006 shares of the company’s stock valued at $1,761,772,000 after buying an additional 744,868 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 2.3%

Eli Lilly and Company stock opened at $1,041.89 on Friday. The firm has a market capitalization of $981.19 billion, a price-to-earnings ratio of 37.01, a price-to-earnings-growth ratio of 1.11 and a beta of 0.48. The firm’s fifty day moving average price is $941.52 and its two-hundred day moving average price is $1,003.33. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter last year, the firm earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 35.82 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is 24.58%.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Retatrutide delivered highly competitive Phase 3 obesity results, with meaningful weight loss that could support a future regulatory filing and expand Lilly’s already dominant obesity portfolio.
• Positive Sentiment: Lilly said it will showcase a broad oncology pipeline at ASCO, including Retevmo, Verzenio, and new data from programs in lung, breast, and blood cancers, highlighting more than just obesity-related growth.
• Positive Sentiment: The company agreed to buy Engage Biologics for up to $202 million, adding non-viral DNA delivery technology and extending its push into genetic medicines beyond obesity.
• Positive Sentiment: Analysts and media coverage remain upbeat on Lilly’s growth story, pointing to strong demand for Mounjaro, Zepbound, and Foundayo and continued upside in the stock.
• Neutral Sentiment: Lilly also completed an $8.9 billion debt offering, which supports funding for acquisitions and R&D but may modestly increase leverage.
• Negative Sentiment: The company disclosed a lawsuit alleging a Trulicity rebate-fraud scheme that cost more than $200 million, a legal overhang that could weigh on sentiment if it develops further.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of recent analyst reports. Wolfe Research reiterated an “outperform” rating and set a $1,350.00 price target on shares of Eli Lilly and Company in a report on Thursday. Wells Fargo & Company raised their target price on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 2nd. Berenberg Bank increased their price target on Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a report on Thursday, February 19th. Finally, CICC Research raised their price objective on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 11th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $1,219.26.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.